UNSPSC 51172149: Stilonium

This classification denotes an antispasmodic with the molecular formula C22H30NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4L5V8Z34JM, chemically known as ethanaminium, n,n,n-triethyl-2-(4-(2-phenylethenyl)phenoxy)- but generally known as stilonium, which bears US NIH Compound Identifier 5824382. As of Q4 2014, STILONIUM remains the US FDA Preferred Term for this commodity. Stilonium bears US NLM identifiers UMLS ID C2828261 and NCI Concept Code C87314. SMILES: CC[N+](CC)(CC)CCOC1=CC=C(C=C1)C=CC2=CC=CC=C2.

UNSPSC 51172149 Stilonium, a Commodity code, encompasses pharmaceutical and specimen collection products and services that state and local governments procure for correctional supervision, pharmacy benefit programs, and multi-agency health supply chains. Recent solicitations show state and local buyers contracting for drug-testing services (specimen collection, immunoassay screening, and confirmatory lab work), direct-to-manufacturer pharmacy programs, and generic pharmaceuticals distributed through established wholesaler networks. The issuing bodies span state health and human services agencies, county criminal justice departments, and multi-state cooperative purchasing alliances serving state and local government facilities. Collin County Community Supervision and Corrections Department (Texas) and the Texas Health and Human Services Commission represent state-level and county-level buyers; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, serves multiple participating states including Minnesota and Oregon.

Recent activity concentrates in Texas and Minnesota. Collin County issued RFP 2026-327 for offender specimen collection and drug testing services on July 9, 2026, with proposals due July 23, 2026; the scope includes staffing two collection sites in Plano and McKinney, operating an Interactive Voice Response system for randomized testing, and conducting immunoassay screening with confirmatory testing (LC/MS/MS or GC/MS), with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026, plus three optional one-year renewals. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs without releasing a formal RFP or budget allocation at that stage. MMCAP posted RFP S1070000015802 on January 20, 2026, with responses due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with awarded vendors effective July 1, 2026; the RFP weighted price competitiveness at 75 percent and required vendors to maintain relationships with at least two of the three wholesalers and comply with cGMP and DSCSA standards.